The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-12. Anything still debated is marked as such rather than presented as settled.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Genealogy was another ethnic marker. While it was likely that Israelite identity was not exclusively based on blood descent, the Israelites used genealogical self-definition to engage in cultural narcissism, though also in self-representation of impropriety and guilt, as shown in the story of their occasionally morally challenging ancestor, Jacob, a man of blessing and promise but also one who "suffers for his triumphs and pays a price for taking the name 'Israel'". This ambiguous characterization foreshadows "the complexities of the Jewish soul". Names were significant in Israelite culture and indicated one's destiny and inherent character. Thus, a name change indicated a 'divine transformation' in one's 'destines, characters and natures'. These beliefs aligned with the Near Eastern cultural milieu, where names were 'intimately bound up with the very essence of being and inextricably intertwined with personality'. In terms of appearance, rabbis described the Biblical Jews as being "midway between black and white" and having the "color of the boxwood tree". Assuming Yurco's debated claim that the Israelites are depicted in reliefs from Merneptah's temple at Karnak is correct, the early Israelites may have wore the same attire and hairstyles as non-Israelite Canaanites. Dissenting from this, Anson Rainey argued that the Israelites in the reliefs looked more similar to the Shasu. Based on biblical literature, it is implied that the Israelites distinguished themselves from peoples like the Babylonians and Egyptians by not having long beards and chin tufts.
Tenkaonian Goren Nashi (テンカオ星人ゴレン・ナシ, Tenkao Seijin Goren Nashi) and Tenkaonian Yam Tomukun (テンカオ星人ヤム・トムクン, Tenkao Seijin Yamu Tomukun): Namunan's partners of the same species who are killed by Chou San. Goren Nashi is voiced by Seiji Fujita (藤田 清二, Fujita Seiji), who also portrays his human form; Yam Tomukun is portrayed by Minoru Nanaeda (七枝 実, Nanaeda Minoru). Mikean Clord (マイク星人クロード, Maiku Seijin Kurōdo): A vine-themed criminal from Planet Mike who is charged with several counts of mass murder and inhuman experimentation stemming from his stealing young women's nutrients to cure his sister Teresa, who is dating Hoji. Despite learning of Clord's goal and being initially torn over allowing him to continue, Hoji ultimately deletes him before he can kill another group of young women. Clord is voiced by Yuuki Tsujimoto (辻本 祐樹, Tsujimoto Yūki), who also portrays his human form. Aladonian Gyanjava (アラドン星人ギャンジャバ, Aradon Seijin Gyanjaba): A cricket-themed bank robber from Planet Aladon who is charged with burglary and child abduction, having killed Yaako's parents to take advantage of her natural ability to manipulate locks. After requesting Agent Abrella's help to access the Deka Base's systems, Yaako betrays Gyanjava and helps the Dekarangers foil his latest robbery. Gyanjava dons a Muscle Gear to evade capture and judgement before piloting a Kaijuki called Cannon Gladiator 4 (キャノングラディエーター4, Kaijūki Kyanon Guradiētā Fō) to crush the Dekarangers, only to be thwarted and judged by Deka Bike Robo.
== Pharmacodynamics == Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) receptor agonist, derived from human GLP-1-(7-37), a less common form of endogenous GLP-1. It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. Liraglutide leads to insulin release in pancreatic beta cells in the presence of elevated blood glucose. This insulin secretion subsides as glucose concentrations decrease and approach euglycemia (normal blood glucose level). It also decreases glucagon secretion in a glucose-dependent manner and delays gastric emptying. Unlike endogenous GLP-1, liraglutide is stable against metabolic degradation by peptidases, with a plasma half-life of 13 hours.
Oral: Capsules: Prometrium (100 mg, 200 mg, 300 mg) Vaginal: Tablets: Endometrin (100 mg); Gels: Crinone (4%, 8%) Intramuscular injection: Oil: Progesterone (50 mg/mL) A 25 mg/mL concentration of progesterone oil for intramuscular injection and a 38 mg/device progesterone intrauterine device (Progestasert) have been discontinued. An oral combination formulation of micronized progesterone and estradiol in oil-filled capsules (brand name Bijuva) is marketed in the United States for the treatment of menopausal symptoms and endometrial hyperplasia. Progesterone is also available in unregulated custom preparations from compounding pharmacies in the United States. In addition, transdermal progesterone is available over-the-counter in the United States, although the clinical efficacy of transdermal progesterone is controversial.
Sources: en.wikipedia.org
== Relation to humans == Arapaima is exploited in many ways by local human populations. Its tongue is thought to have medicinal qualities in South America. It is dried and combined with guarana bark, which is grated and mixed into water. Doses are given to kill intestinal worms. The bony tongue is used to scrape cylinders of dried guarana, an ingredient in some beverages, and the bony scales are used as nail files. Arapaima produce boneless steaks and are considered a delicacy. In the Amazon region, locals often salt and dry the meat, rolling it into a cigar-style package that is then tied and can be stored without rotting, which is important in a region with little refrigeration. Arapaima are referred to as the "cod of the Amazon", and can be prepared in the same way as traditional salted cod. Designers have begun using the skin of the arapaima as leather to make jackets, shoes, and handbags, and to cover furniture. In July 2009, villagers around Kenyir Lake in Terengganu, Malaysia, reported sighting A. gigas. The "Kenyir monster", or "dragon fish" as the locals call it, was claimed to be responsible for the mysterious drowning of two men on 17 June. In August 2018, India Times reported that arapaima has been spotted in the Chalakudy River, following floods in Kerala; their presence in India is attributed to illegal importation for fish farming. The arapaima is depicted on both the flag and the seal of the Department of Ucayali, Peru.
where Ni is the number of molecules of molecular mass Mi. The mass average molecular mass can be determined by static light scattering, small angle neutron scattering, X-ray scattering, and sedimentation velocity. The ratio of the mass average to the number average is called the dispersity or the polydispersity index. The mass-average molecular mass, Mw, is also related to the fractional monomer conversion, p, in step-growth polymerization (for the simplest case of linear polymers formed from two monomers in equimolar quantities) as per Carothers' equation:
Another less insidious tactic journals employ is to publish a large portion of its papers, or at least the papers expected to be highly cited, early in the calendar year. This gives those papers more time to gather citations. Several methods, not necessarily with nefarious intent, exist for a journal to cite articles in the same journal which will increase the journal's impact factor. Beyond editorial policies that may skew the impact factor, journals can take overt steps to game the system. For example, in 2007, the specialist journal Folia Phoniatrica et Logopaedica, with an impact factor of 0.66, published an editorial that cited all its articles from 2005 to 2006 in a protest against the "absurd scientific situation in some countries" related to use of the impact factor. The large number of citations meant that the impact factor for that journal increased to 1.44. As a result of the increase, the journal was not included in the 2008 and 2009 Journal Citation Reports. Coercive citation is a practice in which an editor forces an author to add extraneous citations to an article before the journal will agree to publish it, in order to inflate the journal's impact factor. A survey published in 2012 indicates that coercive citation has been experienced by one in five researchers working in economics, sociology, psychology, and multiple business disciplines, and it is more common in business and in journals with a lower impact factor. Editors of leading business journals banded together to disavow the practice.
Estradiol has been assessed for use by rectal administration in a number of studies. Uses of estradiol by this route have included treatment of menopausal symptoms in postmenopausal women. Rectal administration of estradiol is described as qualitatively and quantitatively similar to vaginal administration of estradiol. The use of estradiol by the rectal route considerably bypasses the liver and hence the first-pass metabolism that occurs with oral estradiol, similarly to other parenteral routes of estradiol such as vaginal and transdermal administration. Irritation of the intestines does not usually occur with rectal estradiol. The use of estradiol by the rectal route is not well-accepted by all individuals, and due to its inconvenience, it has been said that rectal administration of estradiol has gained no practical clinical importance. Lauritzen (1986) reported that 3 hours after a single rectal dose of 1 mg micronized estradiol, estradiol levels increased by 620 pg/mL and estrone levels increased by 120 pg/mL. Subsequently, Lauritzen (1987, 1990) reported that 0.5 mg/day and 1 mg/day rectal estradiol resulted in respective estradiol levels of 363 pg/mL and 515 pg/mL 6 hours following the last dose. These estradiol levels are fairly similar to those achieved by vaginal estradiol. The estradiol-to-estrone ratio of rectal estradiol is about 5:1, which likewise is the same as that of vaginal estradiol.
== References == This article was submitted to WikiJournal of Medicine for external academic peer review in 2022 (reviewer reports). The updated content was reintegrated into the Wikipedia page under a CC-BY-SA-3.0 license (2023). The version of record as reviewed is: Maxim Masiutin, Maneesh Yadav, et al. (2023). "Alternative androgen pathways" (PDF). WikiJournal of Medicine. 10 (1): 3. doi:10.15347/wjm/2023.003. Wikidata Q100737840.
Sources: en.wikipedia.org
The core function of LIMS has traditionally been the management of samples. This typically is initiated when a sample is received in the laboratory, at which point the sample will be registered in the LIMS. Some LIMS will allow the customer to place an "order" for a sample directly to the LIMS at which point the sample is generated in an "unreceived" state. The processing could then include a step where the sample container is registered and sent to the customer for the sample to be taken and then returned to the lab. The registration process may involve accessioning the sample and producing barcodes to affix to the sample container. Various other parameters such as clinical or phenotypic information corresponding with the sample are also often recorded. The LIMS then tracks chain of custody as well as sample location. Location tracking usually involves assigning the sample to a particular freezer location, often down to the granular level of shelf, rack, box, row, and column. Other event tracking such as freeze and thaw cycles that a sample undergoes in the laboratory may be required. Modern LIMS have implemented extensive configurability as each laboratory's needs for tracking additional data points can vary widely. LIMS vendors cannot typically make assumptions about what these data tracking needs are, and therefore vendors must create LIMS that are adaptable to individual environments. LIMS users may also have regulatory concerns to comply with such as CLIA, HIPAA, GLP, and FDA specifications, affecting certain aspects of sample management in a LIMS solution.
Chemoselectivity of NCL : No side-products are formed from reaction with the other functional groups present in either peptide segment (e.g. Asp, Glu side chain carboxylic acids; Lys epsilon amino group; Tyr phenolic hydroxyl; Ser, Thr hydroxyls, etc.).
In February 2012, Ontario passed legislation to allow the expansion of an already existing drug-tracking system for publicly funded drugs to include those that are privately insured. This database will function to identify and monitor patient's attempts to seek prescriptions from multiple doctors or retrieve them from multiple pharmacies. Other provinces have proposed similar legislation, while some, such as Nova Scotia, have legislation already in effect for monitoring prescription drug use. These changes have coincided with other changes in Ontario's legislation to target the misuse of painkillers and high addiction rates to drugs such as oxycodone. As of 29 February 2012, Ontario passed legislation delisting oxycodone from the province's public drug benefit program. This was a first for any province to delist a drug based on addictive properties. The new law prohibits prescriptions for OxyNeo except to certain patients under the Exceptional Access Program including palliative care and in other extenuating circumstances. Patients already prescribed oxycodone will receive coverage for an additional year for OxyNeo, and after that, it will be disallowed unless designated under the exceptional access program. Much of the legislative activity has stemmed from Purdue Pharma's decision in 2011 to begin a modification of OxyContin's composition to make it more difficult to crush for snorting or injecting. The new formulation, OxyNeo, is intended to be preventive in this regard and retain its effectiveness as a painkiller.
== History == The efficacy of bulevirtide was demonstrated in a multi-center, randomized, open-label, parallel-arm phase III trial. In Trial MYR301, participants were randomly assigned to immediate treatment with bulevirtide 8.5 mg once daily for 144 weeks or to delayed treatment with an observational period of 48 weeks followed by bulevirtide 8.5 mg once daily for 96 weeks.
=== Self-medication === In the vast majority of countries, antibiotics can only be prescribed by a doctor and supplied by a pharmacy. Self-medication by consumers is defined as "the taking of medicines on one's own initiative or on another person's suggestion, who is not a certified medical professional", and it has been identified as one of the primary reasons for the evolution of antimicrobial resistance. Self-medication with antibiotics is an unsuitable way of using them but a common practice in resource-constrained countries. The practice exposes individuals to the risk of bacteria that have developed antimicrobial resistance. Many people resort to this out of necessity, when access to a physician is unavailable, or when patients have a limited amount of time or money to see a doctor. This increased access makes it extremely easy to obtain antimicrobials. An example is India, where in the state of Punjab 73% of the population resorted to treating their minor health issues and chronic illnesses through self-medication. Self-medication is higher outside the hospital environment. The prevalence of self-medication in low- and middle-income countries (LMICs) ranges from 8.1% to 93%. Accessibility, affordability, and conditions of health facilities, as well as the health-seeking behavior, are factors that influence self-medication in low- and middle-income countries.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.